Advancements in Pharmaceutical Approaches for Psoriasis Management: A Comprehensive Review

Abstract:: Chronic inflammatory skin conditions like psoriasis have a major negative impact on quality of life. In recent years, there have been remarkable advancements in pharmaceutical approaches to managing psoriasis, including the evaluation of biologics, treatments using tiny molecules, and innovative topical treatments. Biologics, such as IL- 17, IL-23, and TNF-α inhibitors, have changed the way that treatment is administered, offering targeted and efficient options for psoriasis that is moderate to severe. Small molecule therapies, including PDE4 and JAK inhibitors, provide additional therapeutic options, especially for patients with mild to moderate disease or those unresponsive to biologics. Nanotechnology-based treatments, microneedles, and gene editing are emerging as potential innovations to enhance drug delivery and address the underlying genetic mechanisms of the disease. Personalized medicine, driven by biomarker research, is increasingly recognized as a crucial strategy to maximize the results of treatment and minimize adverse effects. Furthermore, the rise of biosimilars offers cost-effective alternatives to traditional biologics, making advanced therapies more accessible. Despite these advancements, challenges such as drug resistance, long-term safety concerns, and limited access to innovative treatments remain. Continued research and development in these areas hold promise for improving long-term psoriasis management and patient outcomes.